Sugammadex has been used clinically since 2008, and it represents the only cyclodextrin neuromuscular blocking reversal agent currently available for patient care. Sugammadex's unique mechanism of action allows it to reverse the effects of aminosteroid neuromuscular blockade rapidly, and pharmacodynamically predictable doses are selected based on quantitative neuromuscular monitoring. The drug has several potential adverse effects, predominantly related to immediate hypersensitivity reactions and bradyarrhythmias, and it can be costly. Overall, when employed appropriately, it represents an efficacious addition to the perioperative pharmaceutical armamentarium with significant utility. Copyright © by the American Association of Nurse Anesthetists.
Barry Swerdlow, Lisa Osborne-Smith. Sugammadex: Pharmacometrics, Clinical Utility, and Adverse Effects. AANA journal. 2022 Apr;90(2):133-140
PMID: 35343895
View Full Text